A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

ConditionHypertension
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorCRISPR Therapeutics AG

About this trial

A Study of CTX340 in Participants with Uncontrolled Hypertension.

Eligibility criteria

Qualifiers

Age: ≥18 and ≤75 years.

Body mass index ≤40 kg/m2.

24-hour mean ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP) measurement of ≥130 mm Hg but ≤160 mm Hg despite treatment

Be on treatment with ≥4 antihypertensive therapies at effective doses, of which ≥1 must be a diuretic.

Disqualifiers

Serum aldosterone and direct renin concentration (or plasma renin activity [PRA]) suggestive of primary aldosteronism

Mean diastolic blood pressure (DBP) ≤65 mm Hg on screening ABPM.

Participants with vascular cause of hypertension which may be amendable to revascularization

Participants with treatable/reversible causes of uncontrolled hypertension

Trial design

Treatments tested in this trial

  • CTX340
  • Placebo

Treatment groups

69 Participants
are divided into 3 treatment groups

Sponsors and collaborators